Cymabay Therapeutics Inc is a biopharmaceutical company in the clinical stage, dedicated to developing therapies aimed at liver and chronic diseases. Its flagship product, seladelpar, targets primary biliary cholangitis, a liver disease, through a specific receptor activation. Additionally, Cymabay is working on a treatment for type 1 diabetes. Originally known as Metabolex, Inc., the company was founded in 1988 and is based in Fremont, California.